Nevertheless, CD7-targeted CAR-T treatment might be of interest also in those patients with a percentage of CD7-negative blasts, since high expression of CD7 in AML patients is associated with more progressive disease and poor prognosis to standard therapy. Here, CD7 is linked to acute myeloid leukemia.